Oncology billing has one characteristic shared with no other specialty: the per-claim value of a single error is higher than an entire month of billing errors in most other practices.
A missed prior authorization on a round of chemotherapy can represent $8,000–$15,000 in denied claims — from a single administration. A J-code that changed on January 1st, applied to a claim from February, generates a denial that may not surface for 45 days. A multi-provider infusion claim where the professional component and the facility component weren’t coordinated correctly results in duplicate billing exposure or underpayment that compounds across every treatment cycle.
The Three Billing Problems That Hit Oncology Practices Hardest
1. Prior Authorization for Every Treatment Cycle
Chemotherapy requires prior authorization — and the authorization is typically cycle-specific, not diagnosis-specific. An authorization for carboplatin/paclitaxel covers a defined number of cycles. When the treatment plan changes — drug substitution, dose modification, cycle extension — a new authorization is required. Practices that don’t track authorization scope against the actual treatment plan administer treatments outside the authorization boundary and receive denials they discover weeks after the patient has already received care.
The authorization window matters too. Most commercial payers require re-authorization after 30–90 days regardless of treatment plan. Tracking authorization expiration dates against infusion schedules, across a panel of active oncology patients on different treatment protocols, requires a specific daily workflow.
2. J-Code Changes and Drug Billing
Chemotherapy drugs are billed using HCPCS J-codes — drug-specific codes updated by CMS each January 1. When a J-code changes, every open authorization and claim template must be updated. A single outdated J-code generates denials across every claim for that drug until the error is caught and corrected. The most common scenario: a drug’s NDC changes mid-year, the J-code updates, and a biller continuing to use the previous year’s code generates a systematic denial pattern that may not be identified for weeks.
3. Chemotherapy Administration Code Complexity
Chemotherapy administration is billed using a tiered CPT code structure. The initial substance infusion (96413) is billed for the first hour. Additional sequential infusions require 96415 for each additional hour of the same drug. Concurrent infusions — a second drug administered simultaneously — use 96417. Each drug in the treatment protocol requires its own administration code with the correct sequencing. Apply the codes incorrectly and the claim either underbills or generates a bundling denial.
An oncology practice came to us after their chemotherapy denial rate had reached 22% — nearly three times the specialty benchmark. The practice had been through two billers in 18 months and was working from a claim template that hadn’t been updated for the January J-code changes.
We pulled 90 days of claims in Epic and identified three systematic problems: outdated J-codes on five drugs causing denials across all claims for those drugs, prior authorization expiration that nobody was tracking (authorizations for six patients had expired mid-cycle), and administration code sequencing that was applying 96413 as the first code regardless of drug sequence in the protocol.
We rebuilt the billing workflow with updated J-codes, established a daily authorization tracking process tied to the infusion schedule, and corrected the administration code sequencing for every active protocol. The denial rate dropped from 22% to 8% within 60 days. The practice recovered $67,000 in previously denied claims within the timely filing window.
Oncology Billing Denial Codes
| Denial Code | Reason | Fix |
|---|---|---|
| CO-4 | Incorrect J-code or administration code | Verify J-code is current for this calendar year; verify administration sequence |
| CO-15 | Prior authorization invalid or expired | Track auth expiration against infusion schedule; re-authorize before cycle continues |
| CO-50 | Non-covered service or formulary exclusion | Verify payer formulary; submit exception request with clinical documentation if off-formulary |
| CO-97 | Bundling — concurrent vs sequential billing | Apply correct 96413/96415/96417 sequence per drug administration order |
| CO-151 | Medical necessity not established | Clinical documentation must support specific chemotherapy protocol per diagnosis |
Frequently Asked Questions
How do you stay current on J-code changes?
Every January 1st, our oncology billing specialists update all active claim templates and authorization tracking with the new HCPCS J-code table. Any mid-year drug changes that generate new J-codes are updated within 48 hours of CMS announcement. We maintain a running J-code change log and flag any claims submitted with outdated codes within the correction window.
How do you track prior authorization across active chemotherapy patients?
Every active oncology patient has an authorization tracking record — drug, authorized number of cycles, authorization expiration date, and flag at 14 days before expiration. The record is reviewed against the infusion schedule daily. No patient receives a cycle without verified active authorization.
What EHR systems do your oncology billers support?
Epic, athenahealth, AdvancedMD, iKnowMed, and Flatiron Health. Oncology practices using a standalone infusion documentation system — Zynx, CureMD Oncology — our billers work with the billing output from those platforms.
A single missed authorization in oncology costs more than an entire month of billing errors in most other specialties. The right workflow prevents it entirely. Book a free 15-minute call — or start the 4-week free pilot.
Related Specialty Billing Services
See our guides for Neurology Billing Services — high-value infusion billing with similar prior authorization complexity — and Internal Medicine Billing Services for practices managing oncology patients alongside primary care.